Ginsburg Geoffrey S, Angrist Misha
Duke University, Duke Institute for Genome Sciences & Policy, Durham, North Carolina, USA.
Personalized Medicine Coalition, 1401 H Street, NW Suite 650, Washington DC 20005, USA.
Per Med. 2006 May;3(2):119-123. doi: 10.2217/17410541.3.2.119.
A recent report from the British Royal Society on the prospects for personalized medicine provides a sobering assessment of the field and its prospects. The report contends that pharmacogenetics has little clinical relevance at the moment and will only progress with the completion of large, cumbersome clinical trials. The report goes on to note that the regulatory infrastructure, medical education initiatives and public deliberation necessary to make personalized medicine a reality are essentially nonexistent, at least so far. In our view, personalized medicine is much more than a hypothetical protocol designed to correlate genotypes with prescriptions. We argue that the development of personalized medicine is a broader phenomenon that is already being practiced in one form or another in many contexts. Both academic medicine and the pharmaceutical industry have a huge stake in bringing pharmacogenetic-based personalized medicine to fruition; we expect both entities to act as drivers of what will be a long-term, iterative process.
英国皇家学会最近发布的一份关于个性化医疗前景的报告，对该领域及其前景给出了一份发人深省的评估。该报告认为，目前药物遗传学与临床的关联性不大，只有在完成大规模、繁琐的临床试验后才会取得进展。报告还指出，使个性化医疗成为现实所需的监管基础设施、医学教育举措和公众讨论基本上不存在，至少目前如此。我们认为，个性化医疗远不止是一种旨在将基因型与处方相关联的假设方案。我们认为，个性化医疗的发展是一个更广泛的现象，已经在许多情况下以某种形式得到实践。学术医学和制药行业在实现基于药物遗传学的个性化医疗方面都有着巨大的利害关系；我们期望这两个实体都能成为这一长期迭代过程的推动者。
